Postvaccinal Encephalitis after ChAdOx1 nCov-19
© 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
The global SARS-CoV-2 pandemic has contributed to more than 163 million confirmed infections and 3.3 million deaths worldwide. The severity of the pandemic has led to an unprecedented effort to develop multiple effective vaccines. Due to excellent safety and efficacy data from clinical trials, several vaccines were approved. We report a case series of postvaccinal encephalitis in temporal correlation to vaccination with ChAdOx1 nCov-19. The diagnostic criteria for possible autoimmune encephalitis were fulfilled. Our patients responded well to immunosuppressive therapy with corticosteroids. The incidence has been estimated to be approximately 8 per 10 million vaccine doses. Complication of postvaccinal encephalitis after ChAdOx1 nCoV-19 vaccination still appear to be very rare, but need to be diagnosed and treated adequately. Large pooled data from observational epidemiologic studies are necessary to verify causality. ANN NEUROL 2021;90:506-511.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:90 |
|---|---|
| Enthalten in: |
Annals of neurology - 90(2021), 3 vom: 01. Sept., Seite 506-511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zuhorn, Frédéric [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B5S3K2V0G8 |
|---|
| Anmerkungen: |
Date Completed 20.09.2021 Date Revised 05.10.2022 published: Print-Electronic CommentIn: Ann Neurol. 2022 Apr;91(4):578. - PMID 34951047 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ana.26182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328688304 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328688304 | ||
| 003 | DE-627 | ||
| 005 | 20231225203453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ana.26182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328688304 | ||
| 035 | |a (NLM)34324214 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zuhorn, Frédéric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postvaccinal Encephalitis after ChAdOx1 nCov-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2021 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Neurol. 2022 Apr;91(4):578. - PMID 34951047 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a The global SARS-CoV-2 pandemic has contributed to more than 163 million confirmed infections and 3.3 million deaths worldwide. The severity of the pandemic has led to an unprecedented effort to develop multiple effective vaccines. Due to excellent safety and efficacy data from clinical trials, several vaccines were approved. We report a case series of postvaccinal encephalitis in temporal correlation to vaccination with ChAdOx1 nCov-19. The diagnostic criteria for possible autoimmune encephalitis were fulfilled. Our patients responded well to immunosuppressive therapy with corticosteroids. The incidence has been estimated to be approximately 8 per 10 million vaccine doses. Complication of postvaccinal encephalitis after ChAdOx1 nCoV-19 vaccination still appear to be very rare, but need to be diagnosed and treated adequately. Large pooled data from observational epidemiologic studies are necessary to verify causality. ANN NEUROL 2021;90:506-511 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a ChAdOx1 nCoV-19 |2 NLM | |
| 650 | 7 | |a B5S3K2V0G8 |2 NLM | |
| 700 | 1 | |a Graf, Tilmann |e verfasserin |4 aut | |
| 700 | 1 | |a Klingebiel, Randolf |e verfasserin |4 aut | |
| 700 | 1 | |a Schäbitz, Wolf-Rüdiger |e verfasserin |4 aut | |
| 700 | 1 | |a Rogalewski, Andreas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of neurology |d 1983 |g 90(2021), 3 vom: 01. Sept., Seite 506-511 |w (DE-627)NLM000198420 |x 1531-8249 |7 nnns |
| 773 | 1 | 8 | |g volume:90 |g year:2021 |g number:3 |g day:01 |g month:09 |g pages:506-511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ana.26182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 90 |j 2021 |e 3 |b 01 |c 09 |h 506-511 | ||